Genital Wart News and Research

RSS

Genital warts (or Condyloma acuminata, venereal warts, anal warts and anogenital warts) is a highly contagious sexually transmitted disease caused by some sub-types of human papillomavirus (HPV).

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

12 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Preventing HPV infection could slow HIV epidemic, say researchers

Men infected with human papillomavirus are at greater risk of becoming infected with human immunodeficiency virus than men who are not HPV positive, according to researchers at the University of North Carolina at Chapel Hill.

29 Apr 2010

Nearly all U.S. states offer HPV vaccine to adolescent girls in juvenile justice facilities: Report

Nearly all U.S. states offer the human papillomavirus vaccine to adolescent girls who have been arrested or detained, according to a new report from The Miriam Hospital and Brown University. The study, published in the May issue of the Journal of Adolescent Health, offers the first nationwide review of HPV vaccination practices among juvenile justice facilities.

29 Apr 2010

Backpacker problem in Australia - binge drinking and unprotected sex

The tourist season may not be quite as healthy for the locals as it was before. In an eight year old study conducted by the Sydney Sexual Health Care Centre some scary facts have come to light. The study was based on about 5,700 backpackers who belonged mostly to the UK or Ireland and were in their mid twenties.

28 Mar 2010

Common beliefs on the spread of sexually transmitted diseases may not apply to HPV: Study

A small new study suggests that some common beliefs about the spread of sexually transmitted diseases may not apply to human papillomavirus, also known as HPV.

26 Mar 2010

Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out

Helix BioPharma Corp. announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts.

22 Mar 2010

Cervical cancer vaccine may protect females from post-surgical recurrence

A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB).

17 Mar 2010

Gardasil vaccine may protect women from post-surgical recurrence of cervical cancer

A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham.

17 Mar 2010

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Anapol Schwartz attorneys Lawrence Cohan and Melissa Fry Hague recently filed two Gardasil vaccine complaints – one on behalf of a Kensington, Calif., family, whose 15-year old daughter died after suffering from severe adverse reactions, and another on behalf of a 19-year old Lapeer, Mich., woman, who has a chronic, autoimmune disorder. The cases, filed in The Court of Federal Claims in Washington, D.C., seek recovery under the National Vaccine Injury Compensation Program.

15 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma Corp. today announced financial results for the second quarter ended January 31, 2010.

10 Mar 2010

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

The University of Texas at San Antonio celebrates the grand opening of its New Venture Incubator, a facility with laboratory, office and meeting spaces to support technology start-ups in the greater San Antonio region. The incubator, housed on UTSA’s Main Campus, will serve as a bridge between San Antonio entrepreneurs and the region’s research and development community.

8 Mar 2010

Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

23 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

HPV vaccination programs may reduce genital diseases

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

6 Feb 2010

Teenage girls are not receiving HPV vaccine, says report

In 2006, the Food and Drug Administration (FDA) approved the Human Papilloma Virus (HPV) vaccine for girls and women ages 9 to 26. As part of Cervical Cancer Awareness Month in January, experts at The University of Texas M. D. Anderson Cancer Center review what we have learned about this controversial vaccine in the past four years.

13 Jan 2010

UAB issues updated guidelines for childhood and teen immunization schedule

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

7 Jan 2010

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009